Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Breda

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Diabetologia|May 29, 2002
Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose toleranceD A Ehrmann, E Breda, M K Cavaghan, et al.
Minerva Chirurgica|March 31, 1993
[Subclavian steal syndrome. Clinical aspects and therapeutic problems]S Perri, G Gallo, M Amendolara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2009
Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) GroupD Lorusso, G Ferrandina, S Pignata, et al.
British Journal of Cancer|May 29, 2008
Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patientsG Ferrandina, M Petrillo, A Carbone, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 3, 2025
Endometrioid borderline ovarian tumour: A multicentre analysis from the MITO-14 studyG Candotti, A Bergamini, M Perrone, et al.
Cancer Chemotherapy and Pharmacology|September 13, 2011
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapyS Pignata, F Amant, G Scambia, et al.
British Journal of Cancer|June 13, 2013
Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovaryG Mangili, J Ottolina, A Gadducci, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 30, 2001
Drug-induced modulation of carcinoembryonic antigen (CEA) expression in neoplastic cells from a patient with rectal cancerD Cappelletti, A Cardillo, E Bonanno, et al.
Oncology|November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trialS Pignata, G Scambia, A Savarese, et al.
British Journal of Cancer|May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) groupS Pignata, G Scambia, C Pisano, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Diabetologia|May 29, 2002
Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose toleranceD A Ehrmann, E Breda, M K Cavaghan, et al.
Minerva Chirurgica|March 31, 1993
[Subclavian steal syndrome. Clinical aspects and therapeutic problems]S Perri, G Gallo, M Amendolara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2009
Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) GroupD Lorusso, G Ferrandina, S Pignata, et al.
British Journal of Cancer|May 29, 2008
Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patientsG Ferrandina, M Petrillo, A Carbone, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 3, 2025
Endometrioid borderline ovarian tumour: A multicentre analysis from the MITO-14 studyG Candotti, A Bergamini, M Perrone, et al.
Cancer Chemotherapy and Pharmacology|September 13, 2011
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapyS Pignata, F Amant, G Scambia, et al.
British Journal of Cancer|June 13, 2013
Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovaryG Mangili, J Ottolina, A Gadducci, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 30, 2001
Drug-induced modulation of carcinoembryonic antigen (CEA) expression in neoplastic cells from a patient with rectal cancerD Cappelletti, A Cardillo, E Bonanno, et al.
Oncology|November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trialS Pignata, G Scambia, A Savarese, et al.
British Journal of Cancer|May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) groupS Pignata, G Scambia, C Pisano, et al.
Pageof 5